PriceTargets.com logo

NASDAQ:RUBY - Rubius Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $13.25
  • Forecasted Upside: 27.65 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$10.38 As of 02/26/2021 01:00 AM ET
▲ +2.36 (29.43%)
1 month | 3 months | 12 months
Get New Rubius Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RUBY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RUBY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$13.25
▲ +27.65% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Rubius Therapeutics in the last 3 months. The average price target is $13.25, with a high forecast of $28.00 and a low forecast of $4.00. The average price target represents a 27.65% upside from the last price of $10.38.
Hold
The current consensus among 5 polled investment analysts is to hold stock in Rubius Therapeutics. This rating has held steady since September 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/4/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
6/2/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
8/31/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
11/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2021SVB LeerinkReiterated RatingMarket Perform$5.00 ➝ $4.00Low
i
1/19/2021Morgan StanleyBoost Price TargetEqual Weight$5.00 ➝ $10.00Low
i
11/11/2020Morgan StanleyBoost Price TargetEqual Weight$4.00 ➝ $5.00Low
i
10/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralHigh
i
8/11/2020HC WainwrightReiterated RatingBuy$28.00High
i
3/13/2020GuggenheimLower Price TargetBuy$23.00 ➝ $11.00High
i
3/13/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$15.00 ➝ $4.00High
i
3/13/2020HC WainwrightLower Price TargetBuy$40.00 ➝ $28.00High
i
Rating by Andrew Fein at HC Wainwright
3/13/2020SVB LeerinkDowngradeOutperform ➝ Market Perform$19.00 ➝ $4.00High
i
Rating by J. Chang at SVB Leerink LLC
1/31/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$9.00Medium
i
11/15/2019HC WainwrightReiterated RatingBuy$40.00High
i
Rating by Andrew Fein at HC Wainwright
9/9/2019Robert W. BairdInitiated CoverageUnderperform$4.00 ➝ $4.00High
i
8/29/2019JPMorgan Chase & Co.Lower Price TargetOverweight$27.00 ➝ $22.00High
i
6/26/2019HC WainwrightInitiated CoverageBuy ➝ Buy$40.00High
i
Rating by A. Fein at HC Wainwright
5/30/2019GuggenheimInitiated CoverageBuy$25.00High
i
12/19/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$37.00 ➝ $34.00High
i
8/13/2018SVB LeerinkInitiated CoverageOutperformHigh
i
Rating by J. Chang at SVB Leerink LLC
8/13/2018Morgan StanleyInitiated CoverageOverweight$37.00High
i
8/13/2018JPMorgan Chase & Co.Initiated CoverageOverweightHigh
i
8/13/2018Jefferies Financial GroupInitiated CoverageBuy$40.00High
i
(Data available from 2/27/2016 forward)
Rubius Therapeutics logo
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $10.38
$8.25
$10.88

50 Day Range

MA: $11.37
$8.02
$14.93

52 Week Range

Now: $10.38
$3.35
$15.99

Volume

5,101,735 shs

Average Volume

721,865 shs

Market Capitalization

$842.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.37

Frequently Asked Questions

What sell-side analysts currently cover shares of Rubius Therapeutics?

The following sell-side analysts have issued research reports on Rubius Therapeutics in the last twelve months: Guggenheim, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for RUBY.

What is the current price target for Rubius Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Rubius Therapeutics in the last year. Their average twelve-month price target is $13.25, suggesting a possible upside of 27.6%. HC Wainwright has the highest price target set, predicting RUBY will reach $28.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $4.00 for Rubius Therapeutics in the next year.
View the latest price targets for RUBY.

What is the current consensus analyst rating for Rubius Therapeutics?

Rubius Therapeutics currently has 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in RUBY, but not buy more shares or sell existing shares.
View the latest ratings for RUBY.

What other companies compete with Rubius Therapeutics?

Other companies that are similar to Rubius Therapeutics include NanoString Technologies, Revolution Medicines, Editas Medicine, Sorrento Therapeutics, Bavarian Nordic A/S, AlloVir, Vericel, Kymera Therapeutics, bluebird bio, Ocugen, BioCryst Pharmaceuticals, C4 Therapeutics, Scholar Rock, Translate Bio and Sangamo Therapeutics.

How do I contact Rubius Therapeutics' investor relations team?

Rubius Therapeutics' physical mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company's listed phone number is 617-679-9600 and its investor relations email address is [email protected] The official website for Rubius Therapeutics is www.rubiustx.com.